Agent for regulating bone formation
AssigneeAnGes MG, Inc.
InventorsHideo Shimizu, Hironori Nakagami, Ryuichi Morishita
Life of this patent
Estimating the term…
Abstract
The present invention provides preventive, ameliorating, and/or therapeutic agents for diseases caused by a disturbed balance between bone formation and bone resorption. The decoys of the present invention induce normal bone metabolism by inhibiting the differentiation-inducing factors of cells involved in bone metabolism. For example, bone resorption can be controlled by using a decoy of the present invention to inhibit NF-κB, a transcriptional regulatory factor that regulates osteoclast differentiation. This method uses a mechanism different from those of previous pharmaceutical agents; therefore, one can expect it to be effective for cases in which existing pharmaceutical agents were not effective.
Claims9
A method for suppressing increase in urinary deoxypyridinoline, comprising administering a pharmaceutical composition comprising an NF-κB decoy to a subject in need thereof.
A bone formation modulating agent, in which a nucleic acid comprising a bone formation-related transcriptional regulatory factor binding sequence is an active ingredient.
A method for modulating bone formation, comprising administering a pharmaceutical composition comprising a bone formation-related transcriptional regulatory factor binding sequence to a subject in need thereof.
Dependencies are inferred from the claim text.